5 Gerardo Musuraca | Meldola (FC)
6 Dorian Forte | Bologna
7 Sarah Tettamanti | Monza
8 Mariarita Sciumè | Milano
9 Chiara Cerrato | Torino
10 Claudia Brunetti | Bari
• IL-17/IL-10 DOUBLE-PRODUCING T CELLS: NEW LINK BETWEEN INFECTIONS,
IMMUNOSUPPRESSION AND ACUTE MYELOID LEUKEMIA
• LEUKEMIC MICROENVIRONMENT AND INFLAMMATION. THE TISSUE
INHIBITOR OF METALLOPROTEINASES-1 (TIMP-1) IMPACTS THE IN VITRO
BEHAVIOUR OF LEUKEMIC CELLS THROUGH CD63/PI3K/AKT/P21 AXIS
• CHIMERIC ANTIGEN RECEPTORS FOR SPECIFIC TARGETING OF ACUTE
MYELOID LEUKEMIA
• EARLY DETECTION OF PULMONARY HYPERTENSION IN PRIMARY
MYELOFIBROSIS: THE ROLE OF ECHOCARDIOGRAPHY, CARDIOPULMONARY
EXERCISE TESTING, AND BIOMARKERS ASSESSMENT
• MAINTENANCE THERAPY IMPROVES SURVIVAL IN PATIENTS ACHIEVING A
COMPLETE RESPONSE: POOLED ANALYSIS OF 4 ITALIAN PHASE III TRIALS IN
NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
• GENOME-WIDE CHARACTERIZATION OF CTCF BINDING SITES AND RELATED
GENE PATHWAYS IN THE PATHOGENESIS OF MYELODYSPLASTIC
SYNDROMES
AULA ROMA | VENERDÌ 13 NOVEMBRE ORE 9.00
11 Chiara Cavallini | Verona
12
13
14
15
16
17
18
19
20
• EXPRESSION AND FUNCTION OF THE TL1A/DR3 AXIS IN CHRONIC
LYMPHOCYTIC LEUKEMIA
Francesca Lazzaroni | Milano
• LEUKEMIA ON A CHIP: HIGH CONTENT PROFILING AT SINGLE-CELL
RESOLUTION
Elena Maria Elli | Monza
• NEUROLOGICAL SYMPTOMS IN ESSENTIAL THROMBOCYTHEMIA: IMPACT
OF JAK2V617F MUTATION AND RESPONSE TO THERAPY
Marzia Cavalli | Roma
• PROGNOSTIC ROLE OF BCL2 MOLECULAR MONITORING IN PATIENTS WITH
EARLY STAGE FOLLICULAR LYMPHOMA
Chiara Milanesi | Pavia
• DIFFERENTIAL CLINICAL EFFECTS OF DIFFERENT MUTATION SUBTYPES
IN CALR-MUTANT MYELOPROLIFERATIVE NEOPLASMS
Roberto Crocchiolo | Rozzano (MI)
• TANDEM AUTOLOGOUS-ALLOGENEIC STEM CELL TRANSPLANTATION AS A
FEASIBLE AND EFFECTIVE PROCEDURE IN HIGH-RISK LYMPHOMA PATIENTS
Simona Caruso | Napoli
• NANOG: A POSSIBLE ROLE IN THE TKI RESISTANCE IN CHRONIC MYELOID
LEUKEMIA
Paola Minetto | Genova
• FLUDARABINE-CONTAINING INDUCTION INCREASES MINIMAL RESIDUAL
DISEASE CLEARENCE AND IMPROVES SURVIVAL IN AML PATIENTS WITH
CONCOMITANT NPM1 AND FLT3-ITD MUTATIONS
Roberto Mina | Torino
• IMPACT OF COMPLETE RESPONSE ON PROGRESSION-FREE SURVIVAL AND
OVERALL SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
TREATED WITH EITHER AUTOLOGOUS STEM CELL TRANSPLANTATION OR
CONVENTIONAL CHEMOTHERAPY: RESULTS OF A POOLED ANALYSIS OF 5
PHASE III TRIALS
Nunziatina Laura Parrinello | Catania • DEFECTIVE NEUTROPHILS CONTRIBUTE TO IMMUNOLOGICAL IMPAIRMENT
IN MULTIPLE MYELOMA
POSTER | ORE 18,30
• IRON RESTRICTION FAVORS ANEMIA AND DISEASE PROGRESSION IN
MOUSE MODELS OF MULTIPLE MYELOMA
• AZACYTIDINE THERAPY IN ELDERLY PREVIOUSLY UNTREATED AML
2 Elisa Coviello | Genova
PATIENTS: COMPARISON WITH CONVENTIONAL CHEMOTHERAPY IN
A MATCHED-PAIRED ANALYSIS
3 Luciana De Luca | Rionero In Vulture (PZ) • PHENOTYPIC CHARACTERIZATION AND PROGNOSTIC ROLE OF
EXTRACELLULAR VESICLES IN CHRONIC LYMPHOCYTIC LEUKEMIA
• PROTEOMIC APPROACH TO IDENTIFY NEW MOLECULAR MARKERS
4 Serena De Matteis | Meldola (FC)
IN CONTROLLING THE PATHOGENESIS OF CLASSICAL HODGKIN
LYMPHOMA
• CLINICAL SIGNIFICANCE OF TRANSFERRIN RECEPTOR 2 AND
5 Augusta Di Savino | Torino
ERYTHROPOIETIN RECEPTOR EXPRESSION IN BONE MARROW CELLS
IN MYELODYSPLASTYC SYNDROMES
• DEFINITION OF THE GENOMIC COMPLEXITY OF ADULT PH+ ACUTE
6 Anna Lucia Fedullo | Roma
LYMPHOBLASTIC LEUKEMIA (ALL). POTENTIAL PROGNOSTIC
IMPLICATION
• THE INTERLEUKIN (IL)-31/IL-31R AXIS CONTRIBUTES TO TUMOR
7 Elisa Ferretti | Genova
GROWTH IN HUMAN FOLLICULAR LYMPHOMA
• PERIPHERALLY INSERTED CENTRAL CATHETERS (PICCS) CAN BE
8 Alessandra Malato | Palermo
SUCCESSFULLY UTILIZED IN HEMATOLOGICAL PATIENTS RECEIVING
INTENSIVE CHEMOTHERAPY OR ALLOGENEIC/AUTOLOGOUS STEM
CELL TRANSPLANTATION
9 Vittorio Simeon | Rionero In Vulture (PZ) • A PYRAZOLO[3,4-D] PYRIMIDINE COMPOUND REDUCES FYN
PHOSPHORYLATION AND INDUCES APOPTOSIS IN LARGE GRANULAR
LYMPHOCYTE LEUKEMIA CELLS
• TARGETING THE P53–MDM2 INTERACTION BY THE SMALL-MOLECULE
10 Stefania Trino | Rionero In Vulture (Pz)
MDM2 ANTAGONIST NUTLIN-3A IN ADULT PHILADELPHIA POSITIVE
ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
1 Jessica Bordini | Milano
under 40 è un’iniziativa riservata ai giovani di età non superiore ai 40 anni che promuove, valorizza
e premia lavori scientifici e progetti di ricerca nel settore dell’Ematologia. I candidati ammessi
verranno invitati a presentare il lavoro durante il final contest.
STEERING COMMITTEE:
SERGIO AMADORI, ROMA | MARIO BOCCADORO, TORINO | PAOLO CORRADINI, MILANO |
ROBIN FOÀ,, ROMA | PELLEGRINO MUSTO, RIONERO IN VULTURE (PZ) | FABRIZIO PANE, NAPOLI
under 40 in hematology
GIOVANI EMATOLOGI A CONFRONTO | 2015
FACULTY:
EMANUELE ANGELUCCI, CAGLIARI | ALBERTO BOSI, FIRENZE | ROBERTO CAIROLI, MILANO |
CLARA CAMASCHELLA, MILANO FRANCESCO DI RAIMONDO, CATANIA | BRUNANGELO FALINI, PERUGIA |
RENATO FANIN, UDINE | FELICETTO FERRARA, NAPOLI GIANLUCA GAIDANO, NOVARA |
MARCO GOBBI, GENOVA | FORTUNATO MORABITO, COSENZA | STEFANO A. PILERI, BOLOGNA |
GIOVANNI PIZZOLO, VERONA | GIORGINA SPECCHIA, BARI | PIER LUIGI ZINZANI, BOLOGNA
TALENT SCOUT TEAM:
NICCOLÒ BOLLI, PERUGIA | ANTONELLA NAI, MILANO | CHIARA PALMI, MONZA | DAVIDE ROSSI, NOVARA |
MARIA ROSARIA SAPIENZA, BOLOGNA | ENRICO TIACCI, PERUGIA
PATROCINI:
SIE - Società Italiana di Ematologia
SIES - Società Italiana di Ematologia Sperimentale
GOLDEN SPONSOR:
SILVER SPONSOR:
FINAL CONTEST: VILLAFRANCA DI VERONA (VR), 12-13 NOVEMBRE 2015
W W W. U N D E R 4 0 . I T
Mattioli 1885 | strada della lodesana 649/sx, 43036 fidenza (pr) | tel 0524 530383 | www.mattioli1885.com
FINAL CONTEST | VILLAFRANCA DI VERONA (VR), 12-13 NOVEMBRE 2015 | HOTEL EXPO VERONA
1 Mariano Di Trapani | Verona
GIOVEDÌ 12 NOVEMBRE
SESSIONE PLENARIA
AULA ROMA
SESSIONI PARALLELE
Ore 13.30
Ore 14.00
Ore 14.15
Ore 14.30
Ore 15.30
Ore 16.45
Ore 18.30
Ore 19.15
Ore 20.45
Welcome Buffet
Registrazione partecipanti
Apertura dei lavori
SIMPOSIO
TERAPIE "CHEMIO-FREE" PER PATOLOGIE ONCO-EMATOLOGICHE.
IL FUTURO È GIÀ PRESENTE?
Moderatori: Michele Cavo, Paolo Corradini
Il Mieloma Multiplo - Silvia Gentili (AN)
Le Sindromi Mielodisplastiche - Mariangela Greco (NO)
I Linfomi - Alice Di Rocco (RM)
Presentazione e discussione dei contributi scientifici
AULE: PARIGI | LONDRA | ROMA
Coffee Break
SESSIONE POSTER
Chiusura dei lavori del primo giorno
Dinner
Ore 9.00
Ore 11.00
Ore 11.15
SESSIONE PLENARIA
AULA ROMA
Ore 12.00
Ore 12.30
SESSIONE PLENARIA
AULA ROMA
2 Alessia Bari | Modena
3 Vittorio Emanuele Muccio | Torino
4 Daniela Guardo | Genova
5 Lara Crucitti | Milano
6 Erica Dander | Monza
7 Stefania Oliva | Torino
8 Alessandra Malato | Palermo
VENERDÌ 13 NOVEMBRE
SESSIONI PARALLELE
AULA PARIGI | GIOVEDÌ 12 NOVEMBRE ORE 15.30
Ore
Ore
Ore
Ore
13.00
14.15
15.30
16.00
Presentazione e discussione dei contributi scientifici
AULE: PARIGI | LONDRA | ROMA
Coffee Break
Presentazione e discussione dei contributi scientifici
AULE: PARIGI | LONDRA | ROMA
SIMPOSIO
Moderatori: Mario Boccadoro, Fabrizio Pane
GLI ANTICORPI MONOCLONALI NEL MIELOMA MULTIPLO:
L’INIZIO DI UNA NUOVA ERA
Francesca Gay (TO)
SIMPOSIO
Moderatori: Mario Boccadoro, Giovanni Pizzolo
NUOVI APPROCCI NEL TRATTAMENTO DELLE PIASTRINOPENIE
Monica Carpenedo (MB)
FERROCHELAZIONE NELLE MALATTIE EMATOLOGICHE TRASFUSIONE
DIPENDENTI: OVERALL SURVIVAL E RISPOSTA EMATOLOGICA
NELLE ESPERIENZE REAL LIFE
Luca Maurillo (RM)
Lunch
Presentazione dei lavori finalisti
Cerimonia di premiazione
Chiusura dei lavori
9 Sara Raponi | Roma
10 Roberta Russo | Napoli
• STANDARDIZED IMMUNOLOGICAL ASSAYS REVEAL UNKNOWN
IMMUNOLOGICAL FUNCTIONS OF MESENCHYMAL STROMAL
CELL-DERIVED EXTRACELLULAR VESICLES
• ABSOLUTE LYMPHOCYTES AND MONOCYTES COUNT, AND THE RATIO:
ASSESSING THE PROGNOSIS OF LYMPHOMAS SIMPLY LOOKING AT
THE COMPLETE BLOOD COUNT
• MULTIPLE MYELOMA: USEFUL SURFACE ANTIGENS TO STUDY PLASMA
CELLS IN THE ERA OF ANTIBODY BASED IMMUNOTHERAPY
• HIGH PROGNOSTIC VALUE OF A 3-GENES MOLECULAR SCORE IN NON
HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH AIDA
2000 PROTOCOL: A RETROSPECTIVE STUDY FROM A REGIONAL REGISTER
• INCIDENCE, RISK FACTORS AND CLINICAL OUTCOME OF LEUKEMIA
RELAPSES WITH LOSS OF THE MISMATCHED HLA AFTER PARTIALLY
INCOMPATIBLE HEMATOPOIETIC STEM CELL TRANSPLANTATION
• PENTRAXIN 3: A CLINICALLY RELEVANT PLASMA BIOMARKER FOR
PREDICTING GRAFT-VERSUS-HOST DISEASE OUTCOME
• REVISED INTERNATIONAL STAGING SYSTEM (R-ISS): A NEW PROGNOSTIC
STRATIFICATION MODEL FOR MULTIPLE MYELOMA PATIENTS (REPORT
FROM INTERNATIONAL MYELOMA WORKING GROUP)
• INTERVENTIONAL STRATEGIES TO CONTAIN COLONIZATION AND
INFECTIONS CAUSED BY CARBAPENEMASE PRODUCING KLEBSIELLA
PNEUMONIA IN HAEMATOLOGICAL MALIGNANCIES
• GENETIC PROFILE OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
WITH ULTRA-STABLE DISEASE
• ERFE-ENCODING FAM132B IN PATIENTS WITH CONGENITAL
DYSERYTHROPOIETIC ANEMIA TYPE II
15 Alessia Santi | Perugia
16 Daniele Tibullo | Catania
17 Elisa Genuardi | Torino
18 Caterina De Benedittis | Bologna
19 Luigia De Falco | Napoli
20 Caterina Ilari | Roma
AULA LONDRA | GIOVEDÌ 12 NOVEMBRE ORE 15.30
1 Angela Mercuri | Verona
2 Eleonora Fonte | Milano
3 Silvia Arcangeli | Monza
4 Francesco Saraceni | Ancona
AULA PARIGI | VENERDÌ 13 NOVEMBRE ORE 9.00
11 Jolanda Sarno | Monza
12 Lara Aprile | Siena
13 Luigi Scaffidi | Verona
14 Fabio Guolo | Genova
• MASS CYTOMETRY ANALYSIS DISSECTS CRLF2-DRIVEN SIGNALING
PATHWAYS IN CHILDHOOD B-CELL PRECURSOR ALL (BCP-ALL)
• PROSPECTIVE EVALUATION OF A PUTATIVE PRO-ATHEROTHROMBOTIC
STATUS AND GENETIC PREDISPOSITION IN THE PATHOGENESIS OF
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE AND OTHER
ATHEROTHROMBOTIC EPISODES IN CHRONIC MYELOID LEUKEMIA
PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
• FATTORI PREDITTIVI DI RISPOSTA MOLECOLARE PROFONDA STABILE IN
PAZIENTI CON LEUCEMIA MIELOIDE CRONICA TRATTATI CON IMATINIB
• HIGH PREDICTIVE VALUE OF PRE TRANSPLANT MINIMAL RESIDUAL
DISEASE ASSESSMENT BY COMBINING WT1 EXPRESSION AND FLOW
CYTOMETRY IN ACUTE MYELOID LEUKEMIA
• DISSECTING AND OVERCOMING THE MOLECULAR AND CELLULAR
MECHANISMS OF RESISTANCE TO BRAF INHIBITORS IN HAIRY
CELL LEUKEMIA
• HEME OXYGENASE-1 NUCLEAR TRANSLOCATION REGULATES
BORTEZOMIB-INDUCED CYTOTOXICITY AND MEDIATES GENOMIC
INSTABILITY IN MYELOMA CELLS
• PROGRESSIVE TELOMERE SHORTENING IS PART OF THE NATURAL HISTORY
OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND IMPACTS CLINICAL
OUTCOME
• CLINICAL IMPACT OF LOW BURDEN BCR-ABL1 MUTATIONS DETECTABLE BY
AMPLICON DEEP SEQUENCING IN PHILADELPHIA-POSITIVE ACUTE
LYMPHOBLASTIC LEUKEMIA PATIENTS: THE TYPE OF MUTATION MATTERS
• GENOTYPE-PHENOTYPE STUDIES IN 70 IRIDA PATIENTS
• IMMUNOGLOBULIN GENE REARRANGEMENTS IN CHINESE AND ITALIAN
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
5 Paolo Gallipoli | Cambridge (UK)
6 Paola Vinci | Monza
7 Immacolata Andolfo | Napoli
8 Antonia Cagnetta | Genova
9 Andrea Ghelli Luserna | Bologna
10 Valentina Griggio | Torino
• IMMUNOPHENOTYPIC ANALYSIS OF HEMATOPOIESIS IN PATIENTS
SUFFERING FROM SHWACHMAN-BODIAN-DIAMOND SYNDROME
• TOLL-LIKE RECEPTOR STIMULATION IN SPLENIC MARGINAL ZONE
LYMPHOMA CAN MODULATE CELL SIGNALING, ACTIVATION AND
PROLIFERATION
• UNRAVELING THE EFFICACY AND SAFETY PROFILES OF ANTI-CD123
CHIMERIC ANTIGEN RECEPTORS (CARS) IN AN IN VITRO MODEL OF
ACUTE MYELOID LEUKEMIA IMMUNOTHERAPY BY INVESTIGATING CAR
BINDING AFFINITY AND DENSITY VARIABLES
• THE ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ACUTE
MYELOID LEUKEMIA TODAY: A GITMO SURVEY ON 970 PATIENTS
• JAK2/STAT5 INHIBITION BY NILOTINIB WITH RUXOLITINIB CONTRIBUTES
TO THE ELIMINATION OF CML CD34+ CELLS IN VITRO AND IN VIVO
• THE CHEMERIN/CHEMR23 AXIS PLAYS A PIVOTAL ROLE IN THE
PATHOGENESIS OF INTESTINAL DAMAGE IN A MURINE MODEL OF
GRAFT VERSUS HOST DISEASE
• FAMILIAL PSEUDOHYPERKALEMIA PATIENTS IN BLOOD DONORS
POPULATION: IMPLICATION FOR PEDIATRIC/NEONATAL TRANSFUSION
• EVIDENCE FOR A ROLE OF THE HISTONE DEACETYLASE SIRT6 IN DNA
DAMAGE RESPONSE OF MULTIPLE MYELOMA CELLS
• IN VITRO AND IN VIVO SINGLE-AGENT EFFICACY OF CHECKPOINT KINASE
INHIBITION IN ACUTE LYMPHOBLASTIC LEUKEMIA
• THE HYPOXIA-INDUCIBLE FACTOR-1ALPHA IS CONSTITUTIVELY
UPREGULATED IN TP53 DISRUPTED CLL CELLS: A POTENTIAL TARGET TO
OVERCOME FLUDARABINE RESISTANCE
AULA LONDRA | VENERDÌ 13 NOVEMBRE ORE 9.00
11 Cesarina Giallongo | Catania
12 Serena De Matteis | Meldola (FC)
13 Anna Borra | Torino
14 Michela Bardini | Monza
15 Antonella Mancusi | Perugia
16 Candida Vitale | Torino
17 Elena Albiero | Vicenza
18 Paola Bonaccorso | Catania
19 Tiziana Ottone | Roma
20 Cristina Clissa | Pesaro
• GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ARE
INCREASED IN MULTIPLE MYELOMA AND ARE DRIVEN BY DYSFUNCTIONAL
MESENCHYMAL STEM CELLS (MSC)
• PENTOSSIFYLLINE INDUCED APOPTOSIS IN CHRONIC LYMPHOCYTIC
LEUKEMIA: NEW INSIGHTS INTO MOLECULAR MECHANISMS
• END-OF-THERAPY DUAL-POINT PET SCAN SHOWS HIGHER ACCURACY
AND PREDICTIVE VALUE COMPARED TO STANDARD PET IN PREDICTING
TREATMENT OUTCOME IN HODGKIN LYMPHOMA
• BET INHIBITOR AS A NOVEL THERAPEUTIC APPROACH FOR THE
TREATMENT OF MLL-REARRANGED INFANT ACUTE LEUKEMIA
• HAPLOIDENTICAL HEMATOPOIETIC TRANSPLANTATION FROM KIR
LIGAND-MISMATCHED DONORS WITH ACTIVATING KIRS REDUCES
NON-RELAPSE MORTALITY
• OFATUMUMAB AND LENALIDOMIDE FOR PATIENTS WITH RELAPSED CLL:
CORRELATION BETWEEN RESPONSES AND IMMUNE CHARACTERISTICS
• STREPTAMER TECHNOLOGY TO ISOLATE MINIMALLY MANIPULATED
CMV-SPECIFIC DONOR LYMPHOCYTES FOR ADOPTIVE TRANSFER IN
PATIENTS SUFFERING OF RECURRENT CMV VIREMIA AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
• MOLECULAR AND PHOSPHOPROTEOMIC CHARACTERIZATION OF PEDIATRIC
T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: IDENTIFICATION
OF NEW PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS
• ROLE OF DNMT3AR882H MUTATION AS A PROGNOSTIC FACTOR IN AML
• LOW-DOSE LENALIDOMIDE AND CYTARABINE COMBO PRODUCES AN HIGH
COMPLETE REMISSION RATE THAT CAN BE PREDICTED BY GENETIC
PROFILING IN AML PATIENTS AGED ≥70 YEARS: FINAL RESULTS OF A
PHASE II STUDY
AULA ROMA | GIOVEDÌ 12 NOVEMBRE ORE 15.30
1 Giulio Bassi | Verona
2 Manuela Gambella | Torino
3 Linda Beneforti | Monza
4 Barbara Castella | Torino
• NOTCH SIGNALING DRIVES BONE MARROW STROMAL CELL-MEDIATED
CHEMORESISTANCE IN ACUTE MYELOID LEUKEMIA
• INVESTIGATION OF MINIMAL RESIDUAL DISEASE (MRD) DURING
MAINTENANCE WITH LENALIDOMIDE IN YOUNG MULTIPLE MYELOMA
PATIENTS: RESULTS FROM THE RV-MM-EMN-441 STUDY
• UNDERSTANDING PIVOTAL MECHANISMS SUSTAINING
TEL/AML1+ CELLS THROUGH AN INNOVATIVE IN VIVO MODEL OF HUMANIZED
PRE-LEUKEMIC NICHE
• ANERGIC BONE MARROW VGAMMA9VDELTA2 T CELLS AS EARLY AND
LONG-LASTING MARKERS OF PD-1-TARGETABLE
MICROENVIRONMENT-INDUCED IMMUNE SUPPRESSION IN HUMAN
MYELOMA